Three findings have suggested that intestinal bacteria participate in the pathogenesis of inflammatory bowel disease (IBD): the histological resemblance of intestinal inflammation caused by infectious agents (Campylobacter jejuni, Yersinia enterocolitica, enteroinvasive Escherichia coli, and Mycobacterium paratuberculosis) to IBD, the presence of granulomas in Crohn's disease (CD) tissue, and the occurrence of the lesions of ulcerative colitis (UC) in a location that normally harbours a luxuriant bacterial population. 1 However, studies attempting to isolate specific pathogens or using antimicrobial treatment in IBD have been inconclusive.2 3 Antibacterial antibody studies have shown that there is increased plasma cell exposure to bacterial antigens in IBD patients, which implies that intraluminal bacteria or their products translocate across the intestinal wall. 4 The occurrence of antibodies against multiple different species and different serotypes suggests that no single bacterial species or strain is implicated. It has been postulated that products of normal luminal bacteria such as endotoxins, peptidoglycans or formylated oligopeptides may underlie the initiation and perpetuation of intestinal inflammation. [5] [6] [7] Indeed, experimental intestinal inflammation has been induced in the rabbit by intracolonic instillation of endotoxin and formalin, in the mouse, rat, and rabbit by intracolonic instillation of formylated oligopeptides, and in the rat by intramural injection of peptidoglycans. [7] [8] [9] Circulating endotoxins have been repeatedly shown in patients with UC and in those with CD using a variety of techniques. 5 10 11 These studies have shown that systemic endotoxaemia is positively correlated with disease activity, radiological extent, the presence of intestinal ulceration, and plasma protein concentrations. It is not clear, however, whether systemic endotoxaemia in IBD is of pathogenic significance or an epiphenomenon reflecting a disrupted intestinal mucosal barrier. Administration of endotoxin to human volunteers and experimental animals induces many of the systemic findings in IBD: fever, tachycardia, chills, release of stress hormones, activation of complement, and release of vasoactive amines and platelet activating factor.'2 Parenteral administration of endotoxin can also result in structural and functional abnormalities in the intestinal mucosa. 13 14 The aim of this study was to investigate whether systemic endotoxins are of pathogenic significance in IBD by searching for evidence of a specific systemic immune response to endotoxin during active disease: production of endotoxin core antibody (EndoCAb) and of tumour necrosis factor (TNF). The glycolipid core of the endotoxin molecule is highly conserved between species and is associated with the endotoxic properties. ' The p55 soluble TNF receptor was measured by ELISA. Briefly, microtitre plates were coated with SR13 monoclonal antibody to soluble p55 overnight at room temperature. Soluble receptors were detected using a second biotinylated monoclonal antibody 5R5 in combination with a streptavidin-peroxidase conjugate. The assay had a sensitivity of 0 5 ng/ml and a range of 0-5-100 ng/ml.
Laboratory measures of disease activity Serum was assayed for C reactive protein (CRP) (precipitin quantitation), c l acid glycoprotein (rate nephelometry), albumin (bromocresol green), and alkaline phosphatase activity. Erythrocyte sedimentation rate (ESR), plasma viscosity (PV), and full haematological profile were also determined. 
Systemic EndoCAb response
There was a significant increase in the plasma IgG EndoCAb concentration in the CD and IC groups when compared with healthy controls (94.3 (3.8)) and with the UC group (Table II) . There was a significant association between the distribution of CD and the mean plasma IgG EndoCAb concentration (Fig 3) : plasma IgG EndoCAb concentration being significantly higher in patients with small bowel CD (929.6 (178.5)) when compared with patients with large bowel CD (340.5 (59.2); p=0.006, Student's t test). In the CD group, there was also a positive correlation between the number of endotoxaemic days and the plasma concentrations of IgG (r.=0 37; p=0.038) and IgM (r5=0.46; p=0.009) EndoCAb.
Treatment received
In the group with UC, four patients were treated with aminosalicylic acid derivatives, six with systemic corticosteroids, and 14 with both aminosalicylic acid derivatives and systemic corticosteroids. In the group with IC, two patients were treated with systemic corticosteroids and four with both aminosalicylic acid derivatives and systemic corticosteroids. In the CD group, nine patients were treated with systemic corticosteroids, 11 with aminosalicylic acid derivatives and systemic corticosteroids, three with systemic corticosteroids and azathioprine, one with azathioprine and an elemental diet, and one with elemental diet alone. 18 20 Extent of colonic disease was measured using a simple scoring system and was found to correlate well with laboratory measures of inflammation in both UC and IC.
The desire to detect endotoxins at low concentrations in human blood has led to development of a range of tests from the epinephrine skin reaction, to the limulus gelation test, which was at least 10 times more sensitive to the limulus amoebocyte lysate assay.22 The limulus amoebocyte lysate bioassay is highly sensitive being capable of detecting femtogram quantities of standard endotoxin. 22 Systemic endotoxaemia has been shown to occur where the intestinal mucosal barrier is damaged by trauma, infection (typhoid fever, E coli enteritis, helminthiais), ischaemia or neoplasia. 23 24 Patients with other intestinal diseases were therefore thought to be unsuitable controls. None of the 100 healthy volunteers was positive for endotoxaemia, which is in agreement with other studies. 22 Systemic endotoxaemia was found in each of the diagnostic groups: at least one endotoxaemic episode was identified in 88% patients with UC (52% samples positive), 75% patients with IC (38% samples positive), and 94% patients with CD (45% samples positive). Systemic endotoxaemia was found to correlate positively with the extent (IC) and activity (UC) of the disease. These results are in close agreement with those of existing reports of systemic endotoxaemia in IBD.51 0 11 Circulating TNF was detected in 40% patients with UC (22% samples positive), 63% patients with IC (25% samples positive), 45% patients with CD (19% samples positive), and none of 100 controls. In the UC group, peak TNF concentration (and the number of TNF positive days) was significantly correlated with clinical (Truelove-Witts) and laboratory measures of disease activity (Cooke-Prior score and ot acid glycoprotein concentration). Also in the UC group a surgical outcome was found to be significantly associated with peak plasma TNF concentrations. MacDonald et al 25 detected TNF in the plasma of two of five children with active CD and two of four with active UC. In addition, Murch et The high incidence of systemic endotoxaemia in this group of patients with active IBD, the significant correlations of systemic endotoxaemia with both disease activity and extent, the presence of circulating TNF (and soluble TNF receptors), and the specific antibody response to endotoxin (IgG EndoCAb) all support a pathogenically significant role for endotoxaemia in these diseases. The difference in EndoCAb concentrations between patients with UC and CD (despite the lack of difference in systemic endotoxin concentrations) is unexplained but may prove of value in discriminating between these two diseases.
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